title: Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma.
abstract: Nasopharyngeal carcinoma (NPC) is common in Southeast Asia and over 40% of NPC tissues have PIK3CA amplification. This study characterized the preclinical activity of a novel potent dual PI3K/mTOR inhibitor, PF-04691502, in five NPC cell lines: CNE-1, HK1, CNE-2, HONE-1 and C666-1, in which all of the cell lines possessed basal and activated expression of Akt and p70S6K. Over 80% inhibition of cell growth in all of these cell lines were achieved after 72 h of PF-04691502 incubation and their IC50 were in hundred nanomolar range. CNE-2, HK1 and HONE-1 were selected to further evaluate the effect of PF-04691502 on cell cycle, apoptosis and Akt downstream signaling. PF-04691502 induced G0/G1 cell cycle arrest and apoptosis at 24 h incubation and it significantly abrogated Akt and its downstream signaling by suppressing the expression of p-mTOR, p-p70S6K, p-Akt(S473, T308), p-S6 and p-4E-BP1, suggesting its effectiveness in inhibition of translation and protein synthesis. Anti-proliferation was also observed in 3D culture system and spheroids formation of NPC cell line HONE-1-EBV was strongly inhibited by PF-04691502. Antitumor activity was observed in CNE-2 xenograft in 2 weeks of 10 mg/kg PF-09641502 treatment to tumor bearing athymic nude mice. Both tumor volume and weight in treatment group were significantly lower than those in vehicle group while no obvious body weight decrease was found, suggesting this working dose was effective and well-tolerated. Additive effects were observed in combination of PF-09641502 with either cisplatin or paclitaxel. There were no synergistic effect observed in drug combination but PF-09641502 alone was effective in treating cisplatin resistant cell lines as compared to its parental control. The beneficial effects of PF-09641502 in both in vitro and in vivo studies for NPC warrant a further investigation.
authors: State Key Laboratory in Oncology in South China, Sir Y.K. Pao Centre for Cancer, Department of Clinical Oncology, Cancer Drug Testing Unit, Hong Kong Cancer Institute and Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, New Territories, Hong Kong, eric@clo.cuhk.edu.hk.
authors: Chi Hang
authors: CH
authors: Wong
authors: Herbert H
authors: HH
authors: Loong
authors: Connie W C
authors: CW
authors: Hui
authors: Cecilia P Y
authors: CP
authors: Lau
authors: Edwin P
authors: EP
authors: Hui
authors: Brigette B Y
authors: BB
authors: Ma
authors: Anthony T C
authors: AT
authors: Chan
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002277:Carcinoma; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000627:therapeutic use; D004353:Drug Evaluation, Preclinical; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D000077274:Nasopharyngeal Carcinoma; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000081082:Phosphoinositide-3 Kinase Inhibitors; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011728:Pyridones / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors*; D047368:Tumor Burden / Q000187:drug effects
chemical_list: C570662:2-amino-8-(4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido(2,3-d)pyrimidin-7(8H)-one; D000970:Antineoplastic Agents; D000081082:Phosphoinositide-3 Kinase Inhibitors; D047428:Protein Kinase Inhibitors; D011728:Pyridones; D011743:Pyrimidines; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D002945:Cisplatin
references: Mol Cancer Ther. 2011 Nov;10(11):2189-99
references: 21750219
references: Clin Cancer Res. 2012 Jul 15;18(14):3901-11
references: 22586300
references: Invest New Drugs. 2013 Jun;31(3):567-75
references: 23143779
references: Invest New Drugs. 2010 Aug;28(4):413-20
references: 19471857
references: Invest New Drugs. 2010 Jun;28(3):326-33
references: 19756373
references: Clin Cancer Res. 2013 Jul 15;19(14):3808-19
references: 23640975
references: Cancer Chemother Pharmacol. 2013 Jun;71(6):1417-25
references: 23546591
references: Cancer Res. 2004 Aug 1;64(15):5251-60
references: 15289331
references: Mol Cancer Ther. 2011 Aug;10(8):1440-9
references: 21632463
references: Toxicol Lett. 2013 Jul 4;220(2):150-6
references: 23639247
references: Breast Cancer Res Treat. 2013 Apr;138(2):369-81
references: 23430223
references: Anticancer Res. 2012 Feb;32(2):445-52
references: 22287731
references: Cancer Lett. 2009 Jun 28;279(1):47-56
references: 19203829
references: Cancer Res. 2006 Feb 1;66(3):1500-8
references: 16452206
references: Oncol Rep. 2008 Feb;19(2):319-28
references: 18202777
references: J Transl Med. 2010 Mar 26;8:30
references: 20338061
references: Cancer Chemother Pharmacol. 2012 Aug;70(2):213-20
references: 22684718
references: Hematol Oncol Clin North Am. 2008 Dec;22(6):1267-78, x
references: 19010273